Table 3.
Literature Overview
| Source | Period | Stage | AC | SCC | Sign. | AC - SCC | ||
|---|---|---|---|---|---|---|---|---|
| n | 5y OS | n | 5yOS | |||||
| Early | ||||||||
| Hopkins et al. [4] | 1970–1985 | I | 124 | 0.6 | 370 | 0.9 | X | −0.3 |
| Shingleton et al. [30] | 1984–1990 | I | 174 | 0.84 | 1136 | 0.84 | 0 | |
| Couvreur et al.a | 2005–2015 | IA-1B1 | 20 | 1 | 52 | 0.89 | 0.11 | |
| Teke et al. [8] | 1996–2000 | IA-IIB | 33 | 0.77 | 218 | 0.73 | 0.04 | |
| Ayhan et al. [31] | 1980–1997 | IB | 67 | 0.84 | 454 | 0.88 | − 0.04 | |
| Eifel et al. [32] | 1960–1989 | IB | 229 | 0.72 | 1538 | 0.81 | X | − 0.09 |
| Nakanishi et al. [34] | 1976–1995 | IB | 104 | 0.88 | 405 | 0.96 | X | −0.08 |
| Galic et al. [3] | 1998–2005 | IB1 | 1094 | 0.85 | 3214 | 0.88 | −0.03 | |
| Shimada et al. [6] | 1997–2003 | IB1 | 184 | 0.92 | 258 | 0.95 | −0.03 | |
| Advanced | ||||||||
| Galic et al. [3] | 1998–2005 | IB2 | 343 | 0.68 | 1701 | 0.69 | −0.01 | |
| Shimada et al. [6] | 1997–2003 | IB2 | 39 | 0.76 | 67 | 0.74 | 0.01 | |
| Irie et al. [33] | 1981–1996 | IB-IIA | 50 | 0.78 | 198 | 0.92 | −0.14 | |
| Shimada et al. [6] | 1997–2003 | IB-IIB | 280 | 0.87 | 540 | 0.83 | 0.04 | |
| Hopkins et al. [4] | 1970–1985 | II | 40 | 0.47 | 186 | 0.62 | X | −0.15 |
| Shingleton et al. [30] | 1984–1990 | II | 102 | 0.57 | 1073 | 0.67 | X | −0.11 |
| Galic et al. [3] | 1998–2005 | IIA | 202 | 0.46 | 1488 | 0.58 | X | −0.13 |
| Shimada et al. [6] | 1997–2003 | IIA | 11 | 0.55 | 83 | 0.87 | X | −0.33 |
| Galic et al. [3] | 1998–2005 | IIB | 424 | 0.46 | 3754 | 0.55 | X | −0.09 |
| Katanyoo et al. [7] | 1980–1997 | IIB | 85 | 0.72 | 170 | 0.71 | 0.01 | |
| Shimada et al. [6] | 1997–2003 | IIB | 46 | 0.63 | 132 | 0.79 | X | −0.16 |
| Couvreur et al.a | 2005–2015 | IB2-IVA | 16 | 0.88 | 91 | 0.63 | 0.25 | |
| Hopkins et al. [4] | 1970–1985 | III | 25 | 0.08 | 114 | 0.36 | X | −0.28 |
| Shingleton et al. [30] | 1984–1990 | III | 47 | 0.3 | 672 | 0.4 | −0.1 | |
| Galic et al. [3] | 1998–2005 | IIIA | 80 | 0.16 | 695 | 0.34 | X | −0.18 |
| Galic et al. [3] | 1998–2005 | IIIB | 238 | 0.2 | 2568 | 0.31 | X | −0.11 |
| Katanyoo et al. [7] | 1995–2008 | IIIB-IVA | 56 | 0.41 | 112 | 0.47 | −0.06 | |
| Shingleton et al. [30] | 1984–1990 | IV | 41 | 0.05 | 287 | 0.13 | −0.08 | |
| Galic et al. [3] | 1998–2005 | IVA | 82 | 0.08 | 622 | 0.17 | −0.09 | |
| Galic et al. [3] | 1998–2005 | IVB | 281 | 0.09 | 959 | 0.06 | 0.04 | |
AC adenocarcinoma, SCC Squamous cell carcinoma, n number, 5yOS 5 year overall survival period: years of enrollment of patients, Sign significance with p-value < 0.05 (all significance levels lie between 0.01 and 0.05); AC-SCC: 5y survival data AC minus 5y survival data SCC resulting in a delta value
acurrent article